

You are cordially invited to a special CME dinner symposium.

Friday, June 23, 2006


NEW VISTAS OF PATHOPHYSIOLOGY AND CHALLENGES IN THE MANAGEMENT OF CHRONIC MIGRAINE



5:10 PM Registration/Dinner
5:30 PM Welcome/Program
7:00 PM Adjourn

Hyatt Regency Century Plaza
Olympic Ballroom
2025 Avenue of the Stars
Los Angeles, California

This CME dinner symposium is not part of the American Headache Society Scientific Meeting.

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and CogniMed Inc.
This activity is supported by an independent educational grant provided by  ALLERGAN

DEAR COLLEAGUE:

On behalf of CogniMed Inc. and the Annenberg Center for Health Sciences at Eisenhower, we cordially invite you to attend this important educational satellite symposium, *New Vistas of Pathophysiology and Challenges in the Management of Chronic Migraine*.

Chronic daily headache (CDH), a syndrome that affects 4% to 5% of the US population, is characterized by more than 15 headaches per month for longer than 3 months. CDH consists of a group of headache disorders, including chronic tension headache, hemicrania continua, new persistent daily headache, and transformed migraine.

The etiology and pathophysiology of transformed migraine involve the central and peripheral nervous systems. Transformed migraine is characterized by an episodic migraine that progresses to more frequent migraine attacks, which then present as CDH. That patients with transformed migraine have "chronic migraine" is not universally accepted. Because a uniform classification of headache types has yet to be established, much confusion exists in this field. Clarification of the definitions of CDH subtypes could improve diagnosis and treatment.

Risk factors play an important role in the development and persistence of CDH. Medication overuse is one potential mechanism leading to transformed migraine. Diagnostic criteria for CDH need to be more readily available for clinicians. Awareness of methods to prevent and control CDH is essential for physicians to effectively treat their patients. Highlighting CDH as a public health concern is a clinical priority in the field of headache and pain.

This educational program is intended for neurologists, primary care clinicians, and other healthcare professionals who have an interest in effectively treating CDH and addressing the diagnostic and therapeutic challenges of this patient population. Current treatments for this disorder range from lifestyle interventions to pharmacologic options. This program will review the current classifications of CDH and discuss evidence-based data on current therapies.

To register for this program, please complete and return the enclosed registration form via fax or mail, or register online at www.cognimed.net. Space is limited, so please respond promptly. We look forward to seeing you June 23 in Los Angeles, California.

Sincerely,


Ninan T. Mathew, MD, FRCPC

Program Chairperson
Director, Houston Headache Clinic
Houston, Texas

LEARNING OBJECTIVES

At the completion of this activity, participants should be better able to

- Discuss the cause, defining characteristics, prevalence, and impact of chronic daily headache (CDH)
- Apply research-based evidence regarding CDH treatment options to make decisions in clinical practice
- Examine current clinical outcome measures to assess efficacy of CDH treatment

INTENDED AUDIENCE

This activity was developed for physicians who treat patients with chronic migraine.

STATEMENT OF NEED

More than 29 million people in the United States suffer from migraine, a type of headache that can be chronic and incapacitating, interfering with school, work, relationships, and activities of daily living. Of these, approximately 5% to 7% will have transformed or chronic migraine. For these migraine sufferers, an accurate diagnosis and understanding of the disease will guide treatment to enhance patient health and function.

ACCREDITATION AND CERTIFICATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Annenberg Center for Health Sciences at

Eisenhower and CogniMed Inc. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center designates this educational activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Statements of Credit will be provided by mail following activity participation and upon completion and return of the evaluation form to CogniMed Inc., 70 South Orange Avenue, Suite 200, Livingston, NJ 07039, or by fax to 877-403-5765. Please allow 4 to 6 weeks for the delivery of your statement.

DISCLOSURE STATEMENT

It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationship with those supporting the activity or any others whose products or services are discussed. Full disclosure will be made in the activity materials.

The program may contain discussion of investigational uses of pharmacologic and nonpharmacologic therapies. Individual clinical judgments should be used in all patient care decisions.

The American Headache Society does not endorse products discussed in this program.

This activity is supported by an independent educational grant from  ALLERGAN

AGENDA

5:10 PM	Registration/Dinner	
5:30 PM	Welcome/Program Overview	Ninan T. Mathew, MD, FRCPC (Chairperson)
5:35 PM	<i>Current Classification of Chronic Daily Headache</i>	Richard B. Lipton, MD
5:55 PM	<i>An Extracranial Perspective of Migraine Pathophysiology</i>	Rami Burstein, PhD
6:20 PM	<i>Systemic and Local Treatments for Chronic Migraine: Efficacy, Safety, and Tolerability Profiles</i>	David W. Dodick, MD
6:40 PM	Clinical Consult: Q&A and Interactive Discussion	Ninan T. Mathew, MD, FRCPC Rami Burstein, PhD David W. Dodick, MD Richard B. Lipton, MD
7:00 PM	Adjourn	

FACULTY:

Ninan T. Mathew, MD, FRCPC
(Chairperson)
Director, Houston Headache Clinic
Houston, Texas

Rami Burstein, PhD
Associate Professor
Departments of Anesthesia and Neurobiology
Harvard Medical School
Boston, Massachusetts

David W. Dodick, MD
Professor of Neurology
Mayo Clinic College of Medicine
Scottsdale, Arizona

Richard B. Lipton, MD
Professor and Vice Chair of Neurology
Professor of Epidemiology and Population Health
Director of Montefiore Headache Unit
Albert Einstein College of Medicine
Bronx, New York

To register for this important program, please complete and return the enclosed form via fax or mail, or register online at www.cognimed.net.

If you require additional information, please call 1-800-720-7779, ext. 316.

Seating is limited; please register early.